Sensus Healthcare (NASDAQ:SRTS) announced its earnings results on Wednesday. The company reported ($0.04) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.01, Fidelity Earnings reports. Sensus Healthcare had a negative return on equity of 8.82% and a negative net margin of 8.65%. The business had revenue of $5.84 million during the quarter, compared to analysts’ expectations of $7.77 million.
Shares of NASDAQ:SRTS traded down $1.67 during midday trading on Thursday, reaching $4.01. The company had a trading volume of 131,700 shares, compared to its average volume of 30,815. Sensus Healthcare has a 1-year low of $3.90 and a 1-year high of $9.23. The firm has a market cap of $93.54 million, a price-to-earnings ratio of -28.64 and a beta of -0.41. The company has a fifty day simple moving average of $5.78 and a two-hundred day simple moving average of $5.73.
A number of equities analysts recently weighed in on SRTS shares. ValuEngine lowered Sensus Healthcare from a “buy” rating to a “hold” rating in a research report on Thursday, October 17th. TheStreet upgraded Sensus Healthcare from a “d+” rating to a “c-” rating in a research report on Monday, August 26th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Sensus Healthcare in a research report on Thursday. B. Riley lowered Sensus Healthcare from a “buy” rating to a “neutral” rating and decreased their price target for the company from $14.00 to $5.50 in a research report on Thursday. Finally, Maxim Group set a $11.00 price target on Sensus Healthcare and gave the company a “buy” rating in a research report on Friday, August 9th. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company’s stock. Sensus Healthcare currently has a consensus rating of “Hold” and a consensus target price of $8.30.
Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Featured Story: Support Level
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.